DAVITA INC (DVA) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:DVA - US23918K1088 - Common Stock
DVA Key Statistics, Chart & Performance
The current stock price of DVA is 114.51 USD. In the past month the price decreased by -3.16%. In the past year, price decreased by -25.07%.
DVA Latest News, Press Relases and Analysis
DVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.7 | 101.72B | ||
| CI | THE CIGNA GROUP | 9.82 | 74.56B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 126.79 | 23.32B | ||
| LH | LABCORP HOLDINGS INC | 15.91 | 20.86B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.81 | 19.33B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.11B | ||
| HIMS | HIMS & HERS HEALTH INC | 61.87 | 7.61B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 37.65 | 6.93B | ||
| CHE | CHEMED CORP | 19.26 | 6.00B | ||
| RDNT | RADNET INC | 186.71 | 5.47B | ||
| OPCH | OPTION CARE HEALTH INC | 21.64 | 5.12B | ||
| WGS | GENEDX HOLDINGS CORP | 70.37 | 3.82B |
Related stock screener links
About DVA
Company Profile
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 76,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
Company Info
DAVITA INC
2000 16th St
Denver COLORADO 80202 US
CEO: Javier J. Rodriguez
Employees: 76000
Phone: 13105362668
DAVITA INC / DVA FAQ
What does DAVITA INC do?
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 76,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
What is the stock price of DAVITA INC today?
The current stock price of DVA is 114.51 USD. The price increased by 0.79% in the last trading session.
What is the dividend status of DAVITA INC?
DVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DVA stock?
DVA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for DVA stock?
The PE ratio for DAVITA INC (DVA) is 12.41. This is based on the reported non-GAAP earnings per share of 9.23 and the current share price of 114.51 USD.
How many employees does DAVITA INC have?
DAVITA INC (DVA) currently has 76000 employees.
What is DAVITA INC worth?
DAVITA INC (DVA) has a market capitalization of 8.08B USD. This makes DVA a Mid Cap stock.
DVA Technical Analysis
DVA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to DVA. DVA scores excellent on profitability, but there are concerns on its financial health.
DVA Financial Highlights
Over the last trailing twelve months DVA reported a non-GAAP Earnings per Share(EPS) of 9.23. The EPS increased by 3.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.8% | ||
| ROA | 4.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
DVA Forecast & Estimates
17 analysts have analysed DVA and the average price target is 141.36 USD. This implies a price increase of 23.45% is expected in the next year compared to the current price of 114.51.
For the next year, analysts expect an EPS growth of 12.69% and a revenue growth 5.89% for DVA